Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
558 stopped studies mapped to Acute Myeloid Leukemia and descendants · 90% state a reason
Over the 558 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00539656 | Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers(Cord Blood) | Phase 1 / Phase 2 | terminated | Oct 4, 2007 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The manufacturer discontinued necessary reagents. | Drug supply |
| NCT02226497 | Telemonitoring Device in Managing Outpatient Care of Patients With Myelodysplastic… | N/A | terminated | Aug 27, 2014 | Fred Hutchinson Cancer Center | Insufficient staff | Other (stated, no rule matched) |
| NCT02435550 | iCare for Cancer Patients | N/A | terminated | May 6, 2015 | University of Florida | Halted due to funding issues. | Funding |
| NCT02231853 | Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells… | Phase 1 | terminated | Sep 4, 2014 | National Heart, Lung, and Blood Institute (NHLBI) | not stated | Not stated |
| NCT02954653 | A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In… | Phase 1 | terminated | Nov 3, 2016 | Pfizer | The study was terminated due to a change in sponsor prioritization. | Other (stated, no rule matched) |
| NCT03483948 | Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia | Phase 1 | terminated | Mar 30, 2018 | Hutchison Medipharma Limited | Slow Enrollment | Enrollment / accrual |
| NCT02343939 | Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute…(ENTO in AML) | Phase 1 / Phase 2 | terminated | Jan 22, 2015 | Gilead Sciences | not stated | Not stated |
| NCT03126864 | Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to… | Phase 1 | terminated | Apr 24, 2017 | M.D. Anderson Cancer Center | Terminated per the PI's request. | Other (stated, no rule matched) |
| NCT03612739 | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2(EPITHINK) | Phase 1 | withdrawn | Aug 2, 2018 | Celyad Oncology SA | Sponsor decision | Sponsor / business decision |
| NCT03195010 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or… | Phase 2 | terminated | Jun 22, 2017 | Fred Hutchinson Cancer Center | Terminated because of slow recruitment and lack of funding support | Enrollment / accrual |
| NCT00568633 | Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML | Phase 3 | terminated | Dec 6, 2007 | Stanford University | Poor accrual | Enrollment / accrual |
| NCT01873495 | Omacetaxine for Consolidation and Maintenance | Phase 2 | terminated | Jun 10, 2013 | Emory University | not stated | Not stated |
| NCT02399917 | Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid… | Phase 2 | terminated | Mar 26, 2015 | M.D. Anderson Cancer Center | This study was terminated early due to response rates not meeting the anticipated minimum of 30%. | Other (stated, no rule matched) |
| NCT01289678 | Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia | Phase 2 | terminated | Feb 4, 2011 | Leo W. Jenkins Cancer Center | Unable to meet accrual goals | Enrollment / accrual |
| NCT03672851 | Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With… | Phase 1 | terminated | Sep 17, 2018 | Second Affiliated Hospital of Xi'an Jiaotong University | adverse effect | Safety / toxicity |
| NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | Phase 2 | terminated | Jan 13, 2006 | Masonic Cancer Center, University of Minnesota | Drug was not available. | Other (stated, no rule matched) |
| NCT01160354 | Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute… | Phase 1 / Phase 2 | terminated | Jul 12, 2010 | M.D. Anderson Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT03395873 | Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are… | Phase 1 | terminated | Jan 10, 2018 | Milton S. Hershey Medical Center | Recent FDA approval of a new drug for the same patient population | Other (stated, no rule matched) |
| NCT02337478 | Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute… | Phase 2 | terminated | Jan 13, 2015 | Wake Forest University Health Sciences | The study was stopped early due to futility. | Efficacy / futility |
| NCT02634827 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid… | Phase 2 | terminated | Dec 18, 2015 | Mayo Clinic | not stated | Not stated |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | Phase 2 | terminated | Sep 14, 2005 | Masonic Cancer Center, University of Minnesota | Accrual Goal Met | Enrollment / accrual |
| NCT02477787 | Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk…(DNKI-4) | Phase 2 | terminated | Jun 23, 2015 | Asan Medical Center | upon recommendation from the Data Monitoring Committee | Other (stated, no rule matched) |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children… | Phase 1 / Phase 2 | terminated | May 14, 2013 | Janssen Research & Development, LLC | EMA/PDCO acknowledged that available results from this study do not support further clinical… | Other (stated, no rule matched) |
| NCT03735446 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a… | Phase 1 | terminated | Nov 8, 2018 | Dana-Farber Cancer Institute | Sponsor Decision | Sponsor / business decision |
| NCT03752138 | TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid… | Phase 1 | withdrawn | Nov 23, 2018 | M.D. Anderson Cancer Center | The supporting pharamceutical company elected not to pursue this study at this time. | Sponsor / business decision |
| NCT02749708 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk… | Phase 1 | terminated | Apr 25, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study drug supply expired and could not be renewed. | Drug supply |
| NCT03291353 | Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute… | Early Phase 1 | withdrawn | Sep 25, 2017 | Michael Boyiadzis | This study has closed due to slow accrual. | Enrollment / accrual |
| NCT02826642 | A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia | Phase 1 | withdrawn | Jul 11, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00808080 | A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell…(AMLCTL) | Phase 1 / Phase 2 | terminated | Dec 15, 2008 | Thomas A. Lane, MD | lack of accrual | Enrollment / accrual |
| NCT02030405 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Jan 8, 2014 | Steven E. Coutre | Regulatory | Other (stated, no rule matched) |
| NCT03381118 | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | Phase 2 | terminated | Dec 21, 2017 | St. Petersburg State Pavlov Medical University | Unexpected toxicity | Safety / toxicity |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or… | Phase 1 / Phase 2 | terminated | Apr 16, 2015 | Spirita Oncology, LLC | Insufficient efficacy in Phase 1 dose-escalation portion of study | Efficacy / futility |
| NCT03187691 | Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal… | Phase 2 | withdrawn | Jun 15, 2017 | Matinas BioPharma Nanotechnologies, Inc. | Protocol redundancy | Other (stated, no rule matched) |
| NCT03705858 | Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia | Phase 1 | withdrawn | Oct 15, 2018 | Joseph Jurcic | Due to difficulty in finalizing the contract | Other (stated, no rule matched) |
| NCT01701323 | Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients… | Phase 1 | terminated | Oct 5, 2012 | Nohla Therapeutics, Inc. | not stated | Not stated |
| NCT03699384 | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients… | Phase 1 / Phase 2 | withdrawn | Oct 9, 2018 | Memorial Sloan Kettering Cancer Center | Study sponsor discontinued support | Other (stated, no rule matched) |
| NCT01849276 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | Phase 1 | terminated | May 8, 2013 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT00655395 | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk… | Phase 1 / Phase 2 | terminated | Apr 9, 2008 | Viron Therapeutics Inc | not stated | Not stated |
| NCT02412475 | Epigenetic Reprogramming in Relapse AML | Phase 1 | terminated | Apr 9, 2015 | Michael Burke | We opened a competing study with the TACL consortium | Other (stated, no rule matched) |
| NCT02614560 | A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem… | Phase 1 / Phase 2 | terminated | Nov 25, 2015 | Seagen Inc. | not stated | Not stated |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | Phase 1 | terminated | Feb 17, 2016 | Plexxikon | Business Decision | Sponsor / business decision |
| NCT02785900 | Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older…(CASCADE) | Phase 3 | terminated | May 30, 2016 | Seagen Inc. | Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33A arm… | Safety / toxicity |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT02676323 | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid… | Phase 1 | terminated | Feb 8, 2016 | St. Jude Children's Research Hospital | Slow accrual | Enrollment / accrual |
| NCT02587871 | Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute… | Phase 2 | withdrawn | Oct 27, 2015 | University of Southern California | PI decided not to pursue study | Other (stated, no rule matched) |
| NCT03365661 | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML | Phase 2 | withdrawn | Dec 7, 2017 | Masonic Cancer Center, University of Minnesota | Sponsor halted study. | Other (stated, no rule matched) |
| NCT00043810 | Study of Gelonin Purging of Autologous Stem Cells for Transplantation | Phase 1 / Phase 2 | terminated | Aug 15, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01904643 | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or… | Phase 1 | terminated | Jul 22, 2013 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00038870 | Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes | N/A | withdrawn | Jun 7, 2002 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Feb 18, 2020source: clinicaltrials